VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LKFT
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LKFTLakefront Biotherapeutics N.V.
$34.39$2.2B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLKFTPrice Target
LKFT logo

Lakefront Biotherapeutics N.V. (LKFT) Price Target Analysis

Updated Nov 6, 2026
Analyst Rating: Hold
Based on 24 analysts

97.5% Below Target

LKFT trades 97.5% below Wall Street's consensus target of $67.93.

Current Price$34.39
Average Target$67.93
Target
Current
Low$33.00
Median$83.74
High$97.00

Analyst Target Range

Forward P/E—
PEG Ratio—
Implied Growth-125.4%
(Declining)
Analyst Spread94.2%
(Wide Disagreement)

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$34.39
Consensus$67.93
High$97.00
Low$33.00

Consensus Scenario Assumptions

The base valuation assumes LKFT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 24 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings Distribution

Breakdown of 24 published analyst recommendations for LKFT

46% hold / mixed conviction
+10
BearishBullish
Weighted analyst sentiment score based on 24 ratings
ConsensusHold
Coverage24 Analysts
Net Score+10
Bull / Bear38% / 17%
Strong Buy00%
Buy938%
Hold1146%
Sell417%
Strong Sell00%
Strong Buy
00%
Buy
938%
Hold
1146%
Sell
417%
Strong Sell
00%
Recommendation Mix38% Buy · 46% Hold · 17% Sell
Buy (9)Hold (11)Sell (4)

LKFT Price Target Analysis

Updated November 18, 2026

As of November 18, 2026, Lakefront Biotherapeutics N.V. (LKFT) has a Wall Street consensus price target of $67.93, based on estimates from 24 covering analysts. With the stock currently trading at $34.39, this represents a potential upside of +97.5%. The company has a market capitalization of $2.25B.

Analyst price targets range from a low of $33.00 to a high of $97.00, representing a 94% spread in expectations. The median target of $83.74 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.

The current analyst consensus rating is Hold, with 9 analysts rating the stock as a Buy or Strong Buy,11 rating it Hold, and 4 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.

From a valuation perspective, LKFT trades at a trailing P/E of 2.6x. Analysts expect EPS to grow -125.4% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $49.58, with bear and bull scenarios of $31.23 and $65.32 respectively. Model confidence stands at 41/100, suggesting limited visibility into future performance.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+59.4%
Industry Consensus
Avg Forward P/E
22.0x
(Fair)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
ARCT logo
ARCTArcturus Therapeutics Holdings Inc.
$227M$7.97$30.50
+282.7%
Buy—21
ACAD logo
ACADACADIA Pharmaceuticals Inc.
$3.1B$18.32$30.05
+64.0%
Buy29.4x37
HALO logo
HALOHalozyme Therapeutics, Inc.
$11.4B$95.97$110.00
+14.6%
Buy11.1x27
EXEL logo
EXELExelixis, Inc.
$17.2B$68.50$53.00
-22.6%
Hold18.5x33
IONS logo
IONSIonis Pharmaceuticals, Inc.
$4.5B$26.96$84.92
+215.0%
Buy—33
INCY logo
INCYIncyte Corporation
$24.1B$119.09$137.67
+15.6%
Buy37.1x45
ABBV logo
ABBVAbbVie Inc.
$517.4B$292.82$308.88
+5.5%
Buy21.0x44
LLY logo
LLYEli Lilly and Company
$1.3T$1415.55$1445.12
+2.1%
Buy40.1x46
PFE logo
PFEPfizer Inc.
$162.3B$28.47$31.13
+9.4%
Hold9.5x40
BMY logo
BMYBristol-Myers Squibb Company
$125.3B$61.35$66.08
+7.7%
Hold9.5x42

LKFT — Frequently Asked Questions

Quick answers to the most common questions about buying LKFT stock.

What is the LKFT stock price target for 2026?

The consensus Wall Street price target for LKFT is $67.93, representing 97.5% upside from the current price of $34.39. With 24 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is LKFT a buy, sell, or hold?

LKFT has a consensus rating of "Hold" based on 24 Wall Street analysts. The rating breakdown is mixed, with 11 Hold ratings making up the largest segment. The consensus 12-month price target of $67.93 implies 97.5% upside from current levels.

Is LKFT stock overvalued or undervalued?

LKFT's current price is $34.39 with a consensus target of $67.93 (97.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.

How high can LKFT stock go?

The most bullish Wall Street analyst has a price target of $97 for LKFT, while the most conservative target is $33. The consensus of $67.93 represents the median expectation. Our quantitative valuation model projects a bull case target of $65 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover LKFT stock?

LKFT is well covered by analysts, with 24 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 11 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the LKFT stock forecast?

The 12-month LKFT stock forecast based on 24 Wall Street analysts shows a consensus price target of $67.93, with estimates ranging from $33 (bear case) to $97 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $50, with bear/bull scenarios of $31/$65.

What is LKFT's fair value based on fundamentals?

Our quantitative valuation model calculates LKFT's fair value at $50 (base case), with a bear case of $31 and bull case of $65. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 41/100.

Should I buy LKFT stock?

Wall Street analysts are very optimistic on LKFT, with a "Hold" consensus rating and $67.93 price target (97.5% upside). 9 of 24 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do LKFT price targets vary so much?

LKFT analyst price targets range from $33 to $97, a 94% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $67.93 consensus represents the middle ground. Our model's $31-$65 range provides an independent fundamental perspective.

Consensus & Technical Research Suite
Open LKFT Terminal

LKFT Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare